ecrin-mdr-crcClinical2020IPD Sharing (as of October 2023): No Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche’s criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungColorectal CancerAdvanced Solid TumorsColorectal NeoplasmsColorectal CancerAdvanced Solid TumorsNon-small Cell Lung CancerColorectal NeoplasmsCarcinoma, Non-small-cell LungInterventionalhttps://newmdr.ecrin.org/Study/2343954HungaryUnited StatesUnited KingdomKenyaSwitzerlandRussiaSpainNew ZealandCanadaSouth KoreaNetherlandsBelgiumNorwayBrazilPolandItalyIsraelAustralia7Erlotinib HydrochlorideSHP2ErlotinibMetastatic Solid TumorGDC-6036GDC-1971KRAS G12CCetuximabInavolisibAtezolizumabBevacizumabECRIN MDRRecruitingfalseA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationThis is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.2020-07-152343954NCT044498742020-000084-222023-506311-18